FDA approves breakthrough pancreatic cancer drug – an oncologist explains how daraxonrasib nearly doubles survival
FDA approval of daraxonrasib significantly improves overall survival in metastatic pancreatic cancer patients.
FDA has approved the KRAS‑targeted drug daraxonrasib for patients with metastatic pancreatic cancer. In a Phase 3 trial of 500 patients, daraxonrasib almost doubled overall survival from 6.7 to 13.2 months, reducing the risk of death by 60% compared with standard chemotherapy, with a manageable rash and other side‑effects.
Pancreatic cancer is one of the deadliest cancers with limited treatment options; daraxonrasib offers a precision‑medicine breakthrough that markedly extends survival and improves quality of life for patients with advanced disease.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.